EMA publishes new Q&A Document on Remote RP Activities
![GDP in Switzerland (GDP 3)](files/eca/userImages/training.img/Z-GDP3-GDP-in-Switzerland-neues-Layout.jpg)
Recommendation
12 September 2024
Basel, Switzerland
Specifics in the Distribution of Medicinal Products (Course in english language!)
The European Medicines Agency (EMA) provides answers to frequently asked questions on Good Manufacturing Practice (GMP) and Good Distribution Practice (GDP) on its website, which have been compiled and agreed by the GMP/GDP Inspectors Working Group.
Now, a new PDF file on Remote RP activities in English language was published. The document was made available on 18 April 2024 in the subsection on GDP requirements.
The document was prepared against the background that a recurring observation made in GDP inspections was that certain RP activities are delegated to employees located outside of the EU/EEA.
According to the document, remote activities by the Responsible Person "could be allowed if accepted by the national competent authority where the authorised site is located", however "RP activities should take place within the EU/EEA (or Northern Ireland) in all cases". In other words, "any RP activities being carried out by a person localised and employed in a country outside of the union should not be accepted."
As there may be country specific rules, it is recommended that wholesalers should consult with their national competent authority in order to determine what requirements apply.
For further information, please see the complete PDF file.
Related GMP News
16.07.2024Templates for Shortage Prevention and Mitigation Plans issued by EMA
16.07.2024New Measures to Report Medicine Disappearances
16.07.2024GDP Non-Compliance Report for Czech Wholesale Distributor
16.07.2024Checklist for Implementation of GDP Principles - Part 9: Transportation
12.06.2024EU adopts Supply Chain Law - Implications for pharmaceutical Companies